Galantamine

DEA Class;  Rx

Common Brand Names; Razadyne ER

Indicated for mild-to-moderate demential of the Alzheimer’s type

For the treatment of mild to moderate vascular dementia

For the treatment of mild to moderately severe Dementia with Lewy bodies

Hypersensitivity

>10%

• Nausea (20-25%)
• Diarrhea (11-15%)
• Vomiting (11-15%)

1-10%

• Abdominal pain
• Anorexia
• Muscle cramp
• Fatigue
• Dizziness
• Headache
• Weight loss
• Depression
• Insomnia
• UTI
• Somnolence
• Anemia
• Syncope

Moderate hepatic or renal impairment: max 8 mg q12hr (conventional) or 16 mg qDay (ER)

Not recommended in severe hepatic or renal impairment

Dose-related increase in risk of syncope reported

Renamed Razadyne from Reminyl in the US to avoid confusion with Amaryl

Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) reported; inform patients and caregivers that therapy should be discontinued at first appearance of skin rash, unless rash is clearly not drug-related; do not resume treatment and consider alternative therapy if signs or symptoms suggest a serious skin reaction

As a cholinesterase inhibitor, therapy is likely to exaggerate neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia

There are no adequate data on developmental risk associated with use in pregnant women

There are no adequate data on developmental risk associated with use in pregnant women